clinical trial · NCT05906862
AMT-253 in Patients With Selected Advanced Solid Tumours
Multitude Therapeutics (Australia) Pty Ltd·phase1·recruiting·n = 54
Advanced Solid TumorAMT-253
brief summary
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-253, in Patients with Advanced Solid Tumors
started
Nov 6, 2023
primary completion
Sep 30, 2026
completion
Dec 30, 2026
last updated
Aug 14, 2025
official title
First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol